KR100435008B1 - 신규한 트롬빈 억제제, 그의 제조방법 및 용도 - Google Patents

신규한 트롬빈 억제제, 그의 제조방법 및 용도 Download PDF

Info

Publication number
KR100435008B1
KR100435008B1 KR10-1998-0700054A KR19980700054A KR100435008B1 KR 100435008 B1 KR100435008 B1 KR 100435008B1 KR 19980700054 A KR19980700054 A KR 19980700054A KR 100435008 B1 KR100435008 B1 KR 100435008B1
Authority
KR
South Korea
Prior art keywords
pab
alkyl
aze
formula
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR10-1998-0700054A
Other languages
English (en)
Korean (ko)
Other versions
KR19990028755A (ko
Inventor
다비드 구스타프슨
얀-에릭 나이스트룀
Original Assignee
아스트라제네카 악티에볼라그
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9502487A external-priority patent/SE9502487D0/xx
Priority claimed from SE9502505A external-priority patent/SE9502505D0/xx
Priority claimed from SE9502504A external-priority patent/SE9502504D0/xx
Priority claimed from SE9503923A external-priority patent/SE9503923D0/xx
Priority claimed from SE9504349A external-priority patent/SE9504349D0/xx
Priority claimed from GBGB9526411.5A external-priority patent/GB9526411D0/en
Application filed by 아스트라제네카 악티에볼라그 filed Critical 아스트라제네카 악티에볼라그
Publication of KR19990028755A publication Critical patent/KR19990028755A/ko
Application granted granted Critical
Publication of KR100435008B1 publication Critical patent/KR100435008B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
KR10-1998-0700054A 1995-07-06 1996-07-02 신규한 트롬빈 억제제, 그의 제조방법 및 용도 Expired - Fee Related KR100435008B1 (ko)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
SE9502487-3 1995-07-06
SE9502487A SE9502487D0 (sv) 1995-07-06 1995-07-06 New amino acid derivatives
SE9502504-5 1995-07-07
SE9502505A SE9502505D0 (sv) 1995-07-07 1995-07-07 New amino acid derivatives
SE9502505-2 1995-07-07
SE9502504A SE9502504D0 (sv) 1995-07-07 1995-07-07 New amino acid derivatives
SE9503923-6 1995-11-07
SE9503923A SE9503923D0 (sv) 1995-11-07 1995-11-07 New amino acid derivatives
SE9504349A SE9504349D0 (sv) 1995-12-05 1995-12-05 New amino acid derivatives
SE9504349-3 1995-12-05
GBGB9526411.5A GB9526411D0 (en) 1995-12-22 1995-12-22 Compounds
GB9526411.5 1995-12-22

Publications (2)

Publication Number Publication Date
KR19990028755A KR19990028755A (ko) 1999-04-15
KR100435008B1 true KR100435008B1 (ko) 2004-07-16

Family

ID=27547251

Family Applications (1)

Application Number Title Priority Date Filing Date
KR10-1998-0700054A Expired - Fee Related KR100435008B1 (ko) 1995-07-06 1996-07-02 신규한 트롬빈 억제제, 그의 제조방법 및 용도

Country Status (30)

Country Link
US (4) US6051568A (enExample)
EP (1) EP0836615B1 (enExample)
JP (1) JP4107682B2 (enExample)
KR (1) KR100435008B1 (enExample)
CN (1) CN1147504C (enExample)
AR (1) AR003440A1 (enExample)
AT (1) ATE238342T1 (enExample)
AU (1) AU709710B2 (enExample)
BR (1) BR9609447A (enExample)
CA (1) CA2226256C (enExample)
CZ (1) CZ298487B6 (enExample)
DE (1) DE69627659T2 (enExample)
DK (1) DK0836615T3 (enExample)
EE (1) EE04500B1 (enExample)
ES (1) ES2197240T3 (enExample)
HU (1) HUP9802315A3 (enExample)
IL (1) IL122813A0 (enExample)
IS (1) IS2081B (enExample)
MX (1) MX9800146A (enExample)
MY (1) MY116539A (enExample)
NO (1) NO324092B1 (enExample)
NZ (2) NZ311854A (enExample)
PL (1) PL185606B1 (enExample)
PT (1) PT836615E (enExample)
RU (1) RU2176645C2 (enExample)
SA (1) SA96170106A (enExample)
SI (1) SI0836615T1 (enExample)
SK (1) SK284695B6 (enExample)
TR (1) TR199800009T1 (enExample)
WO (1) WO1997002284A1 (enExample)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SA96170106A (ar) * 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
JP2000514788A (ja) 1996-06-25 2000-11-07 イーライ・リリー・アンド・カンパニー 抗凝固剤
US6200967B1 (en) 1996-06-25 2001-03-13 Eli Lilly And Company Anticoagulant agents
SE9602646D0 (sv) 1996-07-04 1996-07-04 Astra Ab Pharmaceutically-useful compounds
AR013084A1 (es) 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
SE9704543D0 (sv) * 1997-12-05 1997-12-05 Astra Ab New compounds
JP2003529528A (ja) 1998-04-24 2003-10-07 ３−ディメンショナル ファーマシューティカルズ， インコーポレイテッド プロテアーゼインヒビターとしてのアミノ酸アミジノヒドラゾン、アルコキシグアニジン、およびアミノグアニジン
SE9802938D0 (sv) * 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
WO2000031078A1 (en) * 1998-11-20 2000-06-02 Banyu Pharmaceutical Co., Ltd. 1-acylazetidine derivatives
SE9804313D0 (sv) 1998-12-14 1998-12-14 Astra Ab New compounds
KR20000047461A (ko) * 1998-12-29 2000-07-25 성재갑 트롬빈 억제제
WO2000042059A1 (en) * 1999-01-13 2000-07-20 Astrazeneca Ab New amidinobenzylamine derivatives and their use as thrombin inhibitors
AR023510A1 (es) 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
SE0001803D0 (sv) 2000-05-16 2000-05-16 Astrazeneca Ab New compounds i
SI1311480T1 (sl) * 2000-08-16 2008-12-31 Astrazeneca Ab Novi amidino derivati in njihova uporaba kot trombinski inhibitorji
US6433186B1 (en) * 2000-08-16 2002-08-13 Astrazeneca Ab Amidino derivatives and their use as thormbin inhibitors
RU2300521C2 (ru) * 2000-12-01 2007-06-10 Астразенека Аб Новые производные миндальной кислоты и их применение в качестве ингибиторов тромбина
AR035216A1 (es) 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
SE0102921D0 (sv) * 2001-08-30 2001-08-30 Astrazeneca Ab Pharmaceutically useful compounds
US7129233B2 (en) * 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
US6528503B2 (en) * 2000-12-18 2003-03-04 Merck & Co., Inc. Thrombin inhibitors
WO2002064559A2 (en) * 2001-02-09 2002-08-22 Merck & Co., Inc. Thrombin inhibitors
SE0101762D0 (sv) * 2001-05-18 2001-05-18 Astrazeneca Ab New use
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
UA78195C2 (uk) * 2001-08-30 2007-03-15 Astrazeneca Ab Похідні мигдалевої кислоти та їх застосування як інгібіторів тромбіну, фармацевтична композиція на їх основі
SE0201658D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Immediate release pharmaceutical formulation
SE0201659D0 (sv) * 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
US7524354B2 (en) * 2005-07-07 2009-04-28 Research Foundation Of State University Of New York Controlled synthesis of highly monodispersed gold nanoparticles
TW200827336A (en) * 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU178398B (en) * 1979-06-12 1982-04-28 Gyogyszerkutato Intezet Process for producing new agmatine derivatives of activity against haemagglutination
ATE64956T1 (de) * 1984-06-14 1991-07-15 Ciba Geigy Ag Verfahren zur herstellung von thrombininhibitoren.
HU192646B (en) * 1984-12-21 1987-06-29 Gyogyszerkutato Intezet Process for preparing new n-alkyl-peptide aldehydes
CA1341029C (en) * 1985-02-04 2000-06-20 Michael Kolb Peptidase inhibitors
ZA883953B (en) * 1987-06-05 1990-02-28 Du Pont Peptide boronic acid inhibitors of trypsin-like proteases
US5187157A (en) * 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0362002B1 (en) * 1988-09-01 1995-07-26 Merrell Dow Pharmaceuticals Inc. HIV protease inhibitors
ZA897514B (en) * 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
CA2024697A1 (en) * 1989-09-07 1991-03-08 George P. Vlasuk Protein having anticoagulant properties
TW201303B (enExample) * 1990-07-05 1993-03-01 Hoffmann La Roche
IL99527A (en) * 1990-09-28 1997-08-14 Lilly Co Eli Tripeptide antithrombotic agents
CA2075154A1 (en) * 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
SE9102462D0 (sv) * 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
RU2048719C1 (ru) * 1991-11-06 1995-11-27 Гкн Вальтершайд Гмбх Устройство для соединения сельскохозяйственного орудия с трактором
NZ245039A (en) * 1991-11-12 1994-12-22 Lilly Co Eli N-phenylalanyl and n-phenylglycyl derivatives of the dipeptide of l-azetidine-2-carboxylic acid and l-arginine aldehyde; anti-blood clotting compositions
US5416093A (en) * 1991-11-12 1995-05-16 Eli Lilly And Company Antithrombotic agents
SE9103612D0 (sv) * 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
WO1993018060A1 (en) * 1992-03-04 1993-09-16 Gyógyszerkutató Intézet Kft. New anticoagulant peptide derivatives and pharmaceutical compositions containing the same as well as a process for the preparation thereof
TW223629B (enExample) 1992-03-06 1994-05-11 Hoffmann La Roche
FR2695562B1 (fr) * 1992-09-11 1994-10-14 Synthelabo Utilisation d'un inhibiteur direct de la thrombine pour la fabrication d'un médicament à activité thrombolytique.
US5519193A (en) 1992-10-27 1996-05-21 International Business Machines Corporation Method and apparatus for stressing, burning in and reducing leakage current of electronic devices using microwave radiation
US5583146A (en) * 1992-12-02 1996-12-10 Bristol-Myers Squibb Company Heterocyclic thrombin inhibitors
AU675981B2 (en) * 1992-12-02 1997-02-27 Bristol-Myers Squibb Company Guanidinyl-substituted heterocyclic thrombin inhibitors
US5780631A (en) * 1993-06-03 1998-07-14 Astra Aktiebolag Starting materials in the synthesis of thrombin and kininogenase inhibitors
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
DE4321444A1 (de) * 1993-06-28 1995-01-05 Bernd Prof Dr Clement Pharmazeutische Zubereitung
EP0648780A1 (en) * 1993-08-26 1995-04-19 Bristol-Myers Squibb Company Heterocyclic thrombin inhibitors
TW394760B (en) * 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
CA2140598C (en) * 1994-01-27 2010-03-09 Masahiro Ohshima Prolineamide derivatives
IL112795A (en) * 1994-03-04 2001-01-28 Astrazeneca Ab Peptide derivatives as antithrombic agents their preparation and pharmaceutical compositions containing them
US5726159A (en) * 1994-03-04 1998-03-10 Eli Lilly And Company Antithrombotic agents
US5705487A (en) * 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US5707966A (en) * 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
US5561146A (en) * 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
DE4421052A1 (de) * 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
US5510369A (en) * 1994-07-22 1996-04-23 Merck & Co., Inc. Pyrrolidine thrombin inhibitors
FI972204A0 (fi) * 1994-11-24 1997-05-23 Janssen Pharmaceutica Nv Suonensisäisiä lubelutsoliliuoksia
KR100388185B1 (ko) * 1995-02-17 2003-11-28 애보트 게엠베하 운트 콤파니 카게 트롬빈 억제제로서의 신규 디펩티드 아미딘
US5710130A (en) * 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
US5629324A (en) 1995-04-10 1997-05-13 Merck & Co., Inc. Thrombin inhibitors
SA96170106A (ar) * 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
SE9602263D0 (sv) * 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives

Also Published As

Publication number Publication date
NO980015L (no) 1998-02-25
IS4639A (is) 1997-12-22
US6617320B2 (en) 2003-09-09
CZ421297A3 (cs) 1998-06-17
IL122813A0 (en) 1998-08-16
US20040087647A1 (en) 2004-05-06
US6051568A (en) 2000-04-18
NZ311854A (en) 2000-06-23
HK1008995A1 (en) 1999-05-21
DE69627659T2 (de) 2004-03-04
JPH11508591A (ja) 1999-07-27
CA2226256A1 (en) 1997-01-23
DE69627659D1 (de) 2003-05-28
ATE238342T1 (de) 2003-05-15
CN1147504C (zh) 2004-04-28
AU709710B2 (en) 1999-09-02
NO980015D0 (no) 1998-01-02
SA96170106A (ar) 2005-12-03
PL324483A1 (en) 1998-05-25
MY116539A (en) 2004-02-28
CN1195354A (zh) 1998-10-07
EP0836615A1 (en) 1998-04-22
SI0836615T1 (en) 2003-10-31
EE9700354A (et) 1998-06-15
PL185606B1 (pl) 2003-06-30
NZ509474A (en) 2005-08-26
JP4107682B2 (ja) 2008-06-25
TR199800009T1 (xx) 1998-05-21
US20020042396A1 (en) 2002-04-11
EP0836615B1 (en) 2003-04-23
KR19990028755A (ko) 1999-04-15
AR003440A1 (es) 1998-08-05
HUP9802315A3 (en) 1999-03-01
IS2081B (is) 2006-02-15
HUP9802315A2 (hu) 1999-01-28
ES2197240T3 (es) 2004-01-01
DK0836615T3 (da) 2003-08-11
EE04500B1 (et) 2005-06-15
AU6325396A (en) 1997-02-05
US6921758B2 (en) 2005-07-26
RU2176645C2 (ru) 2001-12-10
US6337343B1 (en) 2002-01-08
NO324092B1 (no) 2007-08-13
BR9609447A (pt) 1999-03-02
CZ298487B6 (cs) 2007-10-17
PT836615E (pt) 2003-09-30
SK180497A3 (en) 1998-11-04
MX9800146A (es) 1998-03-31
CA2226256C (en) 2008-12-30
SK284695B6 (sk) 2005-09-08
WO1997002284A1 (en) 1997-01-23

Similar Documents

Publication Publication Date Title
KR100435008B1 (ko) 신규한 트롬빈 억제제, 그의 제조방법 및 용도
FI119812B (fi) Menetelmä uusien, terapeuttisesti käyttökelpoisten peptidijohdannaisten valmistamiseksi
DE69614579T2 (de) Medikamenten-Vorstufen für Thrombin-Inhibitoren
EP0910573B1 (en) New amino acid derivatives and their use as thrombin inhibitors
WO2019202052A1 (en) Inhibitors of blood coagulation factor xiii
EP0743320A2 (en) Acyl guanidine and amidine prodrugs
RU2262508C2 (ru) Новые ингибиторы тромбина, их получение и применение
TW585853B (en) Novel tripeptide compounds as inhibitors of trypsin-like serine proteases, process for preparation and pharmaceutical composition thereof
HK1008995B (en) New thrombin inhibitors, their preparation and use
UA61057C2 (en) Thrombin inhibitors, a method for preparation , a pharmaceutical composition based thereon and a method for treatment
KR100483869B1 (ko) 신규한 아미노산 유도체 및 트롬빈 억제제로서의 그의 용도
JP3580535B2 (ja) トロンビン阻害剤のプロドラッグ
HK1014719A (en) Acyl guanidine and amidine prodrugs

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

FPAY Annual fee payment

Payment date: 20090409

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20100529

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20100529

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000